External open innovation partner programNovel therapeutic targets in immuno-oncology
We are looking for proposals to identify novel targets that are causative factors of the disease for the treatment of cancer. The target should be secreted, localized in the extracellular matrix or a transmembrane protein with extracellular domains.
At the preclinical stage, selected molecular targets should be supported by clear scientific data derived from in vitro, ex vivo, or animal models. Molecular targets identified in clinical trials (up to Phase II clinical trial) shall also be considered.
Target should give the opportunity to get first-in-class therapeutics.
All proposals will be assessed by our Research & Development team. Based on the level of interest within our research portfolio and the strategic fit of the proposals into argenx long-term research focus, we will enter into discussion with selected candidate(s), potentially leading to funding and partnership agreements.
Proponents that submit proposals of interest will be contacted within three weeks of submission to clarify additional details concerning the underlying science as well as intellectual property rights, timelines, etc.
Submit your proposal online (it takes about 15 minutes) in a form and length that is sufficient to provide the substance of the proposal and its innovativeness. The applicant should also demonstrate his or her expertise in this specific field and target.
While argenx will not share the information beyond its own staff, your initial proposal should contain only non-confidential information.
If your proposal is selected, you will be requested to complete a Confidentiality Disclosure Agreement (CDA).
Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.
argenx is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies. argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases.
The company platform offers the identification of antibodies that allow “unlocking” novel and complex target biology and development of antibody-based drugs designed for longer duration of effect and greater efficacy.
Furthermore, argenx collaborates closely with academic experts, bringing cutting edge antibody discovery technologies to the heart of novel target research. The extraordinary diversity of argenx immune repertoires streamlines target validation, transforming novel monoclonal antibodies proteins into next generation therapeutic antibody programs.
Biowebspin is the leading life sciences network with more than 2 million researchers in Biotech, Pharma and Medtech. Biowebspin has a database of 50,000 companies working on 5000 different R&D projects in more than 50 topics, organized in 10 main types of partnering programs with Academia.